- Home
- ANTX vs NXN Comparison
ANTX vs NXN Comparison
Compare ANTX & NXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- NXN
- Stock Information
- Founded
- ANTX 2017
- NXN 1992
- Country
- ANTX United States
- NXN United States
- Employees
- ANTX 36
- NXN N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- NXN Trusts Except Educational Religious and Charitable
- Sector
- ANTX Health Care
- NXN Finance
- Exchange
- ANTX Nasdaq
- NXN Nasdaq
- Market Cap
- ANTX 38.5M
- NXN 46.2M
- IPO Year
- ANTX 2022
- NXN N/A
- Fundamental
- Price
- ANTX $1.26
- NXN $11.31
- Analyst Decision
- ANTX Buy
- NXN
- Analyst Count
- ANTX 4
- NXN 0
- Target Price
- ANTX $3.50
- NXN N/A
- AVG Volume (30 Days)
- ANTX 79.8K
- NXN 9.7K
- Earning Date
- ANTX 05-13-2025
- NXN 01-01-0001
- Dividend Yield
- ANTX N/A
- NXN 4.23%
- EPS Growth
- ANTX N/A
- NXN N/A
- EPS
- ANTX N/A
- NXN 0.24
- Revenue
- ANTX N/A
- NXN N/A
- Revenue This Year
- ANTX N/A
- NXN N/A
- Revenue Next Year
- ANTX N/A
- NXN N/A
- P/E Ratio
- ANTX N/A
- NXN $48.42
- Revenue Growth
- ANTX N/A
- NXN N/A
- 52 Week Low
- ANTX $0.87
- NXN $10.64
- 52 Week High
- ANTX $3.07
- NXN $12.45
- Technical
- Relative Strength Index (RSI)
- ANTX 44.61
- NXN 33.09
- Support Level
- ANTX $1.18
- NXN $11.26
- Resistance Level
- ANTX $1.33
- NXN $11.47
- Average True Range (ATR)
- ANTX 0.09
- NXN 0.17
- MACD
- ANTX -0.01
- NXN -0.04
- Stochastic Oscillator
- ANTX 42.86
- NXN 36.05
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.